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Abstract
Background: Asthma is a disease of varying severity and differing disease mechanisms. To date, studies aimed at
stratifying asthma into clinically useful phenotypes have produced a number of phenotypes that have yet to be
assessed for stability and to be validated in independent cohorts. The aim of this study was to define and validate,
for the first time ever, clinically driven asthma phenotypes using two independent, severe asthma cohorts: ADEPT
and U-BIOPRED.
Methods: Fuzzy partition-around-medoid clustering was performed on pre-specified data from the ADEPT participants
(n = 156) and independently on data from a subset of U-BIOPRED asthma participants (n = 82) for whom the
same variables were available. Models for cluster classification probabilities were derived and applied to the
12-month longitudinal ADEPT data and to a larger subset of the U-BIOPRED asthma dataset (n = 397). High
and low type-2 inflammation phenotypes were defined as high or low Th2 activity, indicated by endobronchial biopsies
gene expression changes downstream of IL-4 or IL-13.
Results: Four phenotypes were identified in the ADEPT (training) cohort, with distinct clinical and biomarker profiles.
Phenotype 1 was “mild, good lung function, early onset”, with a low-inflammatory, predominantly Type-2, phenotype.
Phenotype 2 had a “moderate, hyper-responsive, eosinophilic” phenotype, with moderate asthma control, mild airflow
obstruction and predominant Type-2 inflammation. Phenotype 3 had a “mixed severity, predominantly fixed
obstructive, non-eosinophilic and neutrophilic” phenotype, with moderate asthma control and low Type-2
inflammation. Phenotype 4 had a “severe uncontrolled, severe reversible obstruction, mixed granulocytic”
phenotype, with moderate Type-2 inflammation. These phenotypes had good longitudinal stability in the
ADEPT cohort. They were reproduced and demonstrated high classification probability in two subsets of the
U-BIOPRED asthma cohort.
Conclusions: Focusing on the biology of the four clinical independently-validated easy-to-assess ADEPT
asthma phenotypes will help understanding the unmet need and will aid in developing tailored therapies.
Trial registration: NCT01274507 (ADEPT), registered October 28, 2010 and NCT01982162 (U-BIOPRED), registered
October 30, 2013.
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Background
Asthma is a disease driven by complex and heterogeneous
pathobiologic processes, involving a multitude of inflam-
matory and structural cell types and a large number of
pro-inflammatory and tissue remodeling mediators [1].
This heterogeneity, may explain, at least in part, the sever-
ity of the disease, including varying risk of exacerbations
[2] and the inconsistency in responses observed across the
spectrum of asthma patients to both standard therapies
and the emerging biologics [3, 4].
Despite a plethora of published studies on asthma
mechanisms, the definition of asthma remains limited to
the description of its key clinical features, with broad ref-
erence to the underlying inflammatory characteristics and
heterogeneity. This is true for both general definitions
provided by the Global Initiative for Asthma guidelines
(GINA, http://www.ginasthma.org/) and definitions of its
severe forms [1], while stratification of asthma is still
based on the combination of symptoms, lung function
and treatment required for symptom control. Recognizing
that clinical and pathobiologic features do not follow a lin-
ear, incremental pattern presented in the GINA guide-
lines, a number of studies of asthmatics with varying
clinical presentations have applied unbiased clustering in
an attempt to define new phenotypes of asthma. These
studies have used a range of clinical variables in combin-
ation with simple, easy to apply, measures of airways in-
flammation assessed in induced sputum [5–8]. Indeed, the
Severe Asthma Research Program (SARP) clustered on
clinical, demographic, and natural history variables from
726 asthmatics, resulting in 5 patient clusters [5]. Subse-
quently, in a subset of these subjects (n = 423), 15 inflam-
matory cellular measures and clinical variables were
included, and 4 clusters were identified [6]. In a recent
SARP report, the dataset was reduced (n = 378) to partici-
pants with exhaled nitric oxide (FENO) and bronchoalve-
olar lavage (BAL) fluid cell counts, and included healthy
controls, resulting in 6 clusters by clustering on 112 clin-
ical, physiologic, and inflammatory variables [7]. Patient
data from the Dose Ranging Efficacy And safety with
Mepolizumab (DREAM) study was clustered on clinical
and biomarker variables [8]. Four clusters were identified
that could be defined by 3 predictors (blood eosinophils,
airway reversibility, and body mass index). However, nei-
ther the longitudinal stability of the described clusters nor
their validation in an independent asthma cohort has re-
ported to date. Furthermore, limited studies to date have
undertaken an in-depth characterization of the molecular
processes that are associated with the clinical phenotypes.
Such analysis is limited to a single study of mild, steroid-
naive asthmatics by Woodruff and colleagues [9] who
assessed gene transcription in the airways of 42 nonsmok-
ing subjects with asthma, 28 nonsmoking healthy controls,
and 16 current smokers without asthma but with mild to
moderate airflow obstruction (disease controls) and ob-
served two broad clusters defined by the expression of
three genes (POSTN, CLCA1 and SERPINB2) induced by
the type-2 (T2) cytokine interleukin (IL)-13. The two clus-
ters, defined by high and low expressions levels of these
three genes, were termed Th2-high and Th2-low, the
latter composed of asthmatic and healthy individuals.
The current study had two main aims. The first aim
was to identify clinical phenotypes defined by a limited
set of clinical variables that are easily acquired and can,
therefore, be used in routine clinical practice or trials,
and to assess their reproducibility and stability over time.
The second aim was to describe these clinical phenotypes
by their molecular characteristics, as assessed by whole
genome expression of bronchial samples acquired by
bronchoscopic biopsies and brushings. The study used
clinical and biomarker data from two independent co-
horts. Initial clustering that created the clinical pheno-
types was performed on clinical data acquired in the
ADEPT (Airway Disease Endotyping for Personalized
Therapeutics) study [10] involving 158 asthmatics. The
phenotypes thereby produced were assessed for stability
within the longitudinal arm of the ADEPT study and
validated for reproducibility using data from a subset of
asthmatics from the U-BIOPRED (Unbiased Biomarkers
for the Prediction of Respiratory Disease Outcome) study
[11] constituting an independent validation cohort.
Methods
Study design and study populations
The ADEPT and U-BIOPRED study designs and study
populations are published elsewhere [10, 11] and are
described briefly here. The current study consisted of a
combination of cross-sectional (ADEPT and U-BIOPRED)
and longitudinal (ADEPT) studies. Participants in both
cohorts were assessed clinically at baseline, using pre-
specified protocols.
Clinical phenotypes were created by clustering 9 clin-
ical variables (see Clustering methodology in the next
paragraph) from the ADEPT study which served as the
training set. Matching datasets from U-BIOPRED, ex-
cluding airway hyperresponsiveness (AHR), which was
not assessed in U-BIOPRED, were used as the validation
set for the ADEPT study-derived clinical phenotypes.
After 3, 6 and 12 months of follow up, the ADEPT study
participants were further reassessed to enable further
validation, i.e. assessment of the stability of the pheno-
types through classification of the followed up partici-
pants into the ADEPT study-derived phenotypes created
with baseline data. Relevant biological samples were col-
lected to define the pathobiologic (transcriptomic) char-
acteristics of the clinical phenotypes. Both the ADEPT
[10] and U-BIOPRED [11] studies collected serum for
protein array analysis. All participants underwent
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bronchoscopy for differential gene expression analysis
by microarray of endobronchial biopsies (in ADEPT)
and epithelial brushings (U-BIOPRED) (reasons for
using different sample types are described below under
“Airway type-2 inflammation high and low phenotype”).
All ADEPT participants underwent sputum induction
at the screening visit, to fulfil inclusion criteria, and
again at the Baseline Visit, to confirm the stability of
their phenotype, while the U-BIOPRED participants
had a single sputum induction.
Detailed inclusion and initial clinical stratification cri-
teria of the two studies are published elsewhere [10, 11].
Briefly, for recruitment purposes, the 158 asthmatic par-
ticipants in the ADEPT cohort were initially classified
into severity groups based on their use of asthma con-
troller medication and lung function as assessed by
forced expiratory volume in one second (FEV1): mild (no
asthma controller medications, FEV1 > 80% of predicted)
(n = 52), moderate (low-moderate dose ICS, FEV1 60-
80% of predicted) (n = 55), or severe (on high-dose ICS,
FEV1 50-80% of predicted) (n = 51). FEV1 ranges were
selected to reflect appropriate medication level (e.g., if
a patient had FEV1 < 60% of predicted, a low-medium
ICS dose may not be appropriate), with a low-bound in
the severe group for safety considerations. All had been
current non-smokers for at least one year, with <10 pack-
year smoking history. The 530 asthmatics from the U-
BIOPRED cohort were initially classified as non-severe
(low-medium dose ICS) (n = 88), non-smoking severe
(high-dose ICS; current non-smokers with <5 pack-
year smoking history) (n = 110), and smoking severe
(high-dose ICS; current or ex-smokers with at least 5
pack-year smoking history) (n = 311). All the asthmatics
on maintenance oral corticosteroids (OCS) in the U-
BIOPRED cohort were classified as severe. A subset of the
U-BIOPRED cohort only was included in this study using
those participants without missing data for the 8 clus-
tering variables described below (n = 397 of 509) (see
Additional file 1: Table S2). The 397 U-BIOPRED par-
ticipants included both participants on maintenance
OCS and smokers, two groups of participants which
were not represented in ADEPT.
Clinical phenotypes were created by clustering 9 clinical
variables (see Clustering methodology in the next para-
graph) from the ADEPT study which served as the train-
ing set. Matching datasets from U-BIOPRED, excluding
airway hyperresponsiveness (AHR), which was not
assessed in U-BIOPRED, were used as the validation set
for the ADEPT study-derived clinical phenotypes. After 3,
6 and 12 months of follow up, the ADEPT study partici-
pants were further reassessed to enable further validation,
i.e. assessment of the stability of the phenotypes through
classification of the followed up participants into the
ADEPT study-derived phenotypes created with baseline
data. Relevant biological samples were collected to define
the pathobiologic (transcriptomic) characteristics of the
clinical phenotypes. Both the ADEPT [10] and U-
BIOPRED [11] studies collected serum for protein array
analysis. All participants underwent bronchoscopy for dif-
ferential gene expression analysis by microarray of endo-
bronchial biopsies (in ADEPT) and epithelial brushings
(U-BIOPRED) (reasons for using different sample types
are described below under “Airway type-2 inflammation
high and low phenotype”. All ADEPT participants under-
went sputum induction at the screening visit, to fulfil in-
clusion criteria, and again at the Baseline Visit, to confirm
the stability of their phenotype, while the U-BIOPRED
participants had a single sputum induction.
Clustering methodology
Figure 1 describes the overall schematic of clustering
analyses. Initial clustering of the clinical data from the
independent ADEPT (#156 of 158) and U-BIOPRED
(#82 of 509) cohorts was performed using the Fuzzy
Partition-around-Medoid (PAM) clustering method [12]
to create the baseline phenotypes. For the purpose of
validation of the identified phenotypes, the GLMnet-
classification model of ADEPT-asthma baseline clinical
clusters (#154 of 158) was then applied to classify the
ADEPT-asthma subjects using the data from the base-
line and 3, 6, and 12 month follow-up visits and the
baseline data of U-BIOPRED participants (#397 of 509).
The discrepancies between the cohort sizes and the
number of patients used were due to missing data for
various clustering variables.
Nine clustering variables were selected because they can
be readily measured in standard clinics: pre-bronchodilator
forced expiratory volume in 1 s (pre-BD FEV1) and forced
vital capacity (FVC) expressed as % predicted, FEV1/FVC
ratio, bronchodilator reversibility (BDR), airway hyper-
responsiveness (AHR), i.e. log-transformed provocative
concentration of methacholine resulting in 20% decline in
FEV1 from baseline (PC20); Asthma Control Questionnaire
(ACQ-7) [13], Asthma Quality of Life Questionnaire
(AQLQ) [14]; log-transformed Fractional Exhaled Nitric
Oxide (FENO) concentration in exhaled breath, and blood
eosinophil counts expressed as absolute counts per μL.
PAM clustering is moderately robust to missing data,
allowing the PC20 variable to be utilized despite a mi-
nority of ADEPT-asthma patients (20 of 158) not having
values for this variable (methacholine challenge was not
performed if FEV1 was <60% predicted). Two subjects in
the mild asthma cohort were excluded because they did
not have valid screening or baseline pre-bronchodilator
spirometry measurements available, resulting in not hav-
ing values for 4 of the 9 variables. Two ADEPT asthma
subjects were missing baseline data for FENO and were
included in the initial clustering but excluded from
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GLMnet classification analyses, described below. There-
fore, 156 ADEPT asthma subjects were included in the ini-
tial clustering, and 154 for GLMnet classification analyses.
Initial clustering
The Fuzzy Partition-around-Medoid (PAM) clustering
method [12] (software: NCSS v8, www.NCSS.com;
NCSS LLC, Kaysville, Utah) used Euclidean distance,
scaled with average absolute deviation, and applied the
‘fuzzifier constant’ set to 1.1 (value selected to optimize
Silhouette and distance metrics). The number of clusters
selected for further analysis was based on maximizing be-
tween cluster distance (normalized Dunn’s partition coeffi-
cient, (Fc(U)) and minimizing within-cluster distance
(normalized Kaufman’s distance partition coefficient,
(Dc(U))) metrics [12]. The fuzzy clustering algorithm as-
signs to each subject a probability of membership to each
of the clusters, with the subject then assigned to the clus-
ter with the highest probability of membership.
Fuzzy PAM was selected because it is robust to out-
liers and missing data, does not make the assumption
that all participants cleanly belong to a single cluster
and because it has advantages over other standard
methods, such as k-means clustering and hierarchical
clusters, as well as traditional PAM. Because of limited
sample sizes, permutation-based methods to identify
stable clusters were not employed. Sensitivity analyses
were performed to assess the robustness of these initial
clusters in ADEPT (removing the medoid subjects and
whole study arms), the longitudinal stability of the clus-
ters, and the homologous clusters observed when cluster-
ing on U-BIOPRED subjects, overcome the limitations of
not employing permutations.
For clustering of ADEPT participants, all 158 asth-
matics from the mild, moderate, and severe study
arms were included, with 2 mild asthmatics excluded
because they did not have valid screening or baseline
pre-bronchodilator spirometry measurements avail-
able. For clustering of U-BIOPRED participants, clus-
tering was performed using the same methods and
variables as ADEPT but excluding PC20 because this
variable was available only in a minority of U-
BIOPRED subjects. Participants with missing data for
any of the 8 clustering variables or those taking main-
tenance OCS were also excluded to ensure the most ro-
bust clustering (n = 82 of 509 total participants, with
additional exclusion of 194 on maintenance OCS, 64
smoking severe asthmatics, 148 with FEV1 out-of-range,
and additional 21 with missing data).
GLMnet classification
The GLMNet multinomial logistic regression classifi-
cation algorithm (R package GLMNet v1.9-8 7 [15],
http://www.jstatsoft.org/v33/i01/) was used with the
R-package Caret (Classification and Regression Training,
v. 6.0-35; http://caret.r-forge.r-project.org/) for model
cross-validation (leave-one-out cross-validation to identify
optimal GLMNet alpha and lambda tuning parameters).
Two models were used. Model A, the optimal clas-
sification model for ADEPT-asthma baseline clusters
(Model A), based on the 8 clinical clustering variables
(excluding PC20), was applied to classify U-BIOPRED
subjects (n = 397, including patients on OCS and
smokers), limited only to those without missing data for
these 8 clustering variables. PC20 was not included in the
classification because this variable was not longitudinally
assessed in ADEPT and was unavailable for most U-
BIOPRED participants. An alternate classification model,
Fig. 1 Schematic of clustering analyses. Fuzzy PAM clustering was used
on 156 ADEPT and 82 U-BIOPRED asthma patients, defining analogous
phenotypes, A1 to A4 for ADEPT and US1 to US4 for U-BIOPRED. GLMnet
classification models for the ADEPT phenotypes was built and applied to
either the ADEPT longitudinal samples (3, 6 and 12 month) or a large
subset of the U-BIOPRED cohort (n= 397)
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Model B, was built for longitudinal assessment of ADEPT
asthma subjects (based on 3, 6, and 12 month data), ex-
cluding blood eosinophil counts (in addition to excluding
PC20) because this variable was only measured at screen-
ing in ADEPT. To classify ADEPT subjects across the 3, 6
and 12 month visits and U-BIOPRED subjects into the de-
termined clinical clusters based on the variables used in
the original clustering of screening/baseline values for
ADEPT-asthma subjects. Subjects were excluded from the
classification analyses if they had missing data for at least
one of the model variables at that time point.
The linear predictor coefficients for Model A and Model
B needed to calculate probabilities of classification to the
ADEPT baseline clinical cluster groups are reported in
Additional file 1: Table S3. The probability for classification
of subject i to outcome class k = c (of K outcome classes) is
determined by first calculating the set of linear predictors
ƒ(k,i) for subject i at each outcome class k: f(k, i) = ∑m =
0
M(βm, k ⋅Xm,i), where βm,k is the linear predictor function
coefficient for predictor m at outcome class k (with the
coefficient at predictor m= 0 is the constant for the linear
predictor function for class k) and Xm,i is the value of pre-
dictor m for subject i.
The probability for classification of subject i to out-
come class c [Pr(Yi = c)] is the ratio of the exponentiated
linear predictor for outcome class c over the sum of the
exponentiated linear predictors across the K linear pre-
dictors for subject i: Pr(Yi = c) = e
f(c,i)/∑k = 1
K ef(k,i). The
outcome class with the highest probability for subject i
is the outcome class assigned to the subject.
An interactive calculator (file: ADEPT_clinical_cluster.-
Classification_calculator.Model_A.xlsx) allowing readers
to input values for the 8 clustering variables, with the
ADEPTclinical cluster assignment and classification prob-
abilities automatically calculated for ‘Model A’.
Biologic sample acquisition and analysis
Bronchoscopic sampling and transcriptomic analysis
Endobronchial biopsies and epithelial brushings, taken
at bifurcations of sub-segmental airways in the lower
lobes, were immediately preserved in RNAlater® solution
and then maintained at −70 °C [10, 11]. RNA was ex-
tracted using Qiagen miRNeasy kit (Qiagen; German-
town, MD) and amplified with NuGen ovation pico
WTA kit (NuGen Technologies; San Carlos, CA). The
cDNA was analyzed using the Affymetrix HG-U133 +
PM microarray platform (Affymetrix, Santa Clara, CA).
CEL files were normalized, assessed for quality control
to exclude technical outliers (chip image analysis,
Affymetrix GeneChip QC, RNA degradation analysis,
distribution analysis, principal components analysis, and
correlation analysis), and re-normalized using the robust
multi-array (RMA) method. The log2-normalized data
matrix was imported into OmicSoft ArrayStudio
software (Cary, NC; www.omicsoft.com) for subsequent
analysis. For ADEPT biopsies and U-BIOPRED brush-
ings, batch effects from RNA processing sets were ob-
served (2 sets for each sample type), with the batch
effect adjusted in the data matrices using linear model-
ing of batch (as random factor) and cohort. A log2-in-
tensity threshold of 5.5 for ADEPT biopsies and 4.75 for
U-BIOPRED brushings was established as the limit of re-
liable quantification (LOD) based on the 90th percentile
signal of merged nonspecific probesets distribution in
the array and by the inflection point of maximum vari-
ance with decreasing signal in a standard deviation vs.
mean intensity plot across all probesets. Probesets with
mean log2 intensity above this threshold in at least one
of the 4 study cohorts were considered quantifiable and
included in subsequent analyses (24033 and 21363 pro-
besets for biopsies and brushings, respectively).
Induced sputum (IS) sampling and analysis
The sputum induction and processing protocols are
published in detail elsewhere [10, 11, 16]. They differed
in respect of duration of induction (maximum three 7-
min sessions of nebulization in ADEPT and four 5-min
sessions in U-BIOPRED) and concentration of hyper-
tonic saline (increasing concentrations of 3, 4, and 5%
for ADEPT and 0.9 to 4.5% for U-BIOPRED).
For both cohorts, mucoid portions of sputum were
selected and treated with dithiothreitol for this study in
all participants [17]. Sputum supernatant and cytospin
slides for differential cell counts were prepared by stand-
ard methods. Standard differential staining and counting
was performed centrally. For U-BIOPRED, assessments
of a maximum of 400 inflammatory cells on Diff-Quick
stained cytospins were performed centrally with the out-
come of the cytospin analysis. Sample viability ≥50% and
a threshold of ≤ 40% squamous cells was the default for
samples being made available for analysis. For both stud-
ies, only samples with squamous cell content ≤30% from
cytospin differential counts were included in the ana-
lyses. For ADEPT, a significant proportion of subjects
had only a screening or only a baseline sample available
that passed quality control standards. Therefore, the mean
(differential cell counts) or geometric mean (analyte, gene
expression measurements) of screening and baseline mea-
surements was used for subsequent analyses.
Serum sampling and analysis
Serum was collected using standard Serum Separation
Tubes (SST), frozen within 30 min and subsequently
used for quantification of 1129 serum analytes applying
the SomaScan v3 platform. Results for serum total im-
munoglobulin E (IgE) are presented from this panel,
defining high IgE levels as those above the 95th percentile
of the HV distribution. In previous evaluations of the
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platform in asthmatics and HV, IgE measurements highly
correlated (Pearson’s correlation coefficient r > 0.9) with
those obtained from standard ELISA-based assays (data
not shown).
Airway type-2 inflammation high and low phenotype
For ADEPT, airway Th2-high status was defined on the
basis of biopsy CCL26 gene expression (from microarray
data) beyond the healthy control distribution, which also
coincided with the limit of reliable quantification (LOQ) for
the CCL26 probeset. Periostin (POSTN) gene expression
(from microarray data) beyond the healthy control distribu-
tion was evaluated as an additional indicator of T2-high
status. Endobronchial brushings samples from ADEPT
were limited in sample size and therefore not applicable for
assigning airway Th2-high status for subjects across the
clinical clusters.
For U-BIOPRED, endobronchial brushings were selected
as the airway sample type to evaluate Th2-high status be-
cause this was the sample type with the largest sample size
and most overlap with other sample types (biopsies, spu-
tum). Because CCL26 expression was below LOQ for most
subjects across the study cohorts in U-BIOPRED biopsies
and was also below LOQ in the brushings, an alternative
Th2-activity indicator was selected, namely our own IL-13
ex vivo stimulation gene signature (IL-13 IVS) in endobron-
chial epithelial air-liquid interface cultures. The signature
(genes in signature listed in Additional file 1: Table S4) was
defined by selecting genes commonly induced by IL-13
stimulation across 3 independent sets of experiments (data
not shown). Enrichment was evaluated on a per-subject
basis using the R-Bioconductor package Gene Set Variation
Analysis (GSVA, v 1.14.1) [18]. Subjects with enrichment
scores (ES) beyond the 95th percentile of healthy control
distribution were classified as airway T2-high.
Phadiatop® testing
The ImmunoCAP Phadiatop test (USA or Europe regional
test, depending on the patients’ respective regions) (http://
www.phadia.com/en-GB/5/Products/ImmunoCAP-Assays
/1/) [19] was used to determine the atopic status of
patients. ImmunoCAP Phadiatop is a blood test in which
results are expressed as positive or negative. A positive
Phadiatop® result indicates that the patient is atopic. A
negative result indicates that the patient is non-atopic, i.e.
not sensitized to inhalant allergens.
Results
The ADEPT clinical phenotypes
The ADEPT asthmatics (n = 156) were partitioned into
clusters, i.e. clinical phenotypes, based on baseline data
of the 9 clustering variables. Partitioning the asthma
population into four clusters was determined to be opti-
mal based on maximizing between-cluster Silhouette
metric Fc(U) and minimizing within-cluster distance
metric Dc(U). The Fc(U)/Dc(U) values for options with
2, 3, 4, and 5 clusters were: 0.742/0.110, 0.768/0.080,
0.786/0.079 (optimal), and 0.772/0.082, respectively.
>75% of participants in each cluster had >80% probabil-
ity for their assigned phenotype, and only one subject
per phenotype had <50% probability of ‘belonging’ to
their phenotype (Fig. 2). The clinical and biomarker
characteristics of the 4 ADEPT phenotypes (Clusters A1
to A4) are shown in Fig. 3 and Table 1 and graphically
summarized in Fig. 4.
Phenotype A1 (‘mild, normal lung function, early onset,
low inflammation’) comprised mostly mild asthmatics
(mean ACQ-7: 0.5) and the vast majority (93%) were not
currently on ICS. This was the phenotype with the lowest
mean age-of-onset (15 yrs), BDR and AHR, and preserved
lung function that was not different from healthy partici-
pants. Their inflammatory burden was low, based on
mean FENO levels, the second lowest blood and sputum
eosinophil counts, and the lowest sputum neutrophil
counts.
Phenotype A2 (‘moderate, mild reversible obstruction,
hyper-responsive, highly atopic, eosinophilic’) contained
mostly moderate (52%) and to a lesser degree severe
asthmatics (32%), as defined at the time of recruitment,
characterized by mild, reversible airflow obstruction, and
moderate asthma activity (mean ACQ-7: 1.1). However,
this phenotype had the most hyper-responsive asth-
matics, as measured by methacholine PC20, with the
highest degree of eosinophilic inflammation (based on
FENO and blood and sputum eosinophils), and they
were the most atopic (based on total and specific serum
IgE (Phadiatop®)).
Phenotype A3 (‘mixed severity, mild reversible obstruc-
tion, non-eosinophilic, neutrophilic’) consisted of a mix
of asthmatics with mild (27%), moderate (43%), and se-
vere (31%) disease. The majority were reasonably well-
controlled and had mild airflow obstruction and AHR,
less BDR (approximately 1/3 participants irreversible)
and reduced FVC. Cluster A3 had the lowest FENO, the
least eosinophilic inflammation, the lowest rate of atopy,
but the highest sputum neutrophils.
Phenotype A4 (‘severe uncontrolled, severe reversible
obstruction, mixed granulocytic) asthmatics were de-
rived predominantly from the severe (63%) and to a
lesser extent moderate (26%) asthmatics. They were
generally the most severe and uncontrolled, with the
greatest airflow obstruction, highest BDR, and high
degree of AHR and were characterized by prominent
mixed eosinophilic/neutrophilic inflammation. Al-
though this phenotype had similar high proportions
of serum IgE-high participants as Phenotype A2, the
rate of atopy (Phadiatop® test, see Methods) was
lower, similar to Cluster A3.
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All 9 clustering variables significantly varied across
the 4 ADEPT phenotypes as shown in Fig. 3 and
Table 1, which report additional clinical, biomarker,
and demographic variables. When restricting analysis
to moderate and severe asthma, the 9 clustering vari-
ables also significantly varied across Phenotypes A2,
A3, and A4 (Table 2).
The ADEPT phenotypes resist perturbation
Sensitivity analyses were performed to confirm ro-
bustness of the clusters to perturbations of removing
groups of subjects. In the first sensitivity analysis,
only 1 of 152 subjects changed cluster assignment
after excluding the ‘medoid’ subject defining each
cluster group. Next, only 4 of 104 subjects from ori-
ginal clusters 2, 3, and 4 changed cluster assignment
after the mild asthma cohort was excluded, with 3
clusters selected for analysis. Similarly, when the
moderate asthma cohort was excluded, only 4 of 101
subjects changed cluster assignment. Only when the
severe cohort was excluded was there a marked de-
terioration in cluster formation, with 37 of 105 chan-
ging cluster assignment, specifically with Group 4 not
well-forming in this scenario. This was not unex-
pected given that the original Group 4 consisted
mostly of severe asthma subjects.
The ADEPT phenotypes are stable longitudinally
Applying “Model B” (excluding blood eosinophils and
PC20) to classify ADEPT participants for the baseline, 3,
6 and 12-month visits, stratified by the original baseline
clustering assignment, 24 of 147 participants (16%) had
a discordant baseline classification relative to their ori-
ginally assigned baseline phenotype (i.e., 16% error rate
in classification performance). By comparison using
Model A (including blood eosinophils but not PC20) to
classify baseline samples, discordance was reduced to a
4% error in classification to the originally assigned
phenotype (Fig. 2). Fig. 5 displays the frequency of sub-
jects that maintain or change phenotype classification
across the longitudinal visits. In general, the majority of
participants had stable phenotype assignments through-
out the 12-month duration of the study. The Pearson’s
Contingency Coefficients representing the within-subject
consistency of classified phenotype across visits were
0.81, 0.74, 0.76, and 0.78 for actual baseline phenotypes
A1, A2, A3, and A4, respectively. The overall discord-
ance for classified vs. originally assigned phenotypes was
31%, 31%, and 40% for the 3, 6, and 12 month visits
(compared to the baseline discordance error rate of 16%)
(Fig. 5). Original baseline Phenotype A4 showed the
most changes at follow-up visits, with 39%, 40%, and
40% of participants with discordant classifications at the
Fig. 2 Probability of cluster membership. The probability of cluster membership for the assigned cluster (i.e., the cluster with maximum
probability) output from the Fuzzy-PAM clustering algorithm is reported for each subject from a ADEPT-asthma cohorts (baseline) and
b U-BIOPRED adult asthma cohorts. The classification probability from the GLMnet classification model A of the 8 clustering variables
(excluding PC20 variable) is reported for (c) ADEPT asthma subjects (baseline), with discordantly classified subjects shown with red symbols, and
d U-BIOPRED asthma, stratified for systemic corticosteroid use (blue, no; red, yes)
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3, 6, and 12 month visits, respectively. Additional file 1:
Figure S1 shows how subjects changed cluster classifi-
cations over time for subjects having discordant classi-
fications for at least one-time point compared to the
original, baseline clustering assignment. Case-reports
for associated changes in clinical and biomarker vari-
ables are described in Additional file 1: Figure S2 for
subjects having discordant classifications compared to
baseline (one random subject per baseline cluster selected
for presentation) and in Additional file 1: Figure S3 for
subjects having concordant classifications across visits
compared to baseline assignment (one random subject
per baseline cluster selection for presentation).
The ADEPT matched U-BIOPRED sub-population also
optimally partitions into 4 phenotypes
For the U-BIOPRED cohort [11], 82 out of 397 participants
were selected for clustering based on similar clinical inclu-
sion criteria as ADEPT participants excluding U-BIOPRED
participants on OCS as well as smokers. When compared
to ADEPT moderate-severe asthmatics, the restricted U-
BIOPRED set had slightly lower FEV1 (mean ± standard
Fig. 3 Clustering variables, sputum granulocytes, and biopsy CCL26 distributions in ADEPT clinical phenotypes. The values (y-axis) for the indicated
variables (indicated at top of the plot) are shown for ADEPT asthma participants stratified by fuzzy-PAM clinical clusters (x-axis). Data presented as symbols
representing individual participants and summarized by box (inter-quartile range and median) & whiskers (range), with ‘+’ indicating the mean. PreBD,
pre-bronchodilator; WBC, white blood cells
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Table 1 Clinical, biomarker, and demographic characteristics of ADEPT clusters at baseline
Variablea Healthy
(n = 31)
Cluster A1
(n = 28)
Cluster A2
(n = 44)
Cluster A3
(n = 49)
Cluster A4
(n = 35)
P-value
Mean [Geo.Mean] ± SD
FEV1, pre-bd, % predicted 106.1 ± 13.5 103.5 ± 11.8 77.4 ± 10.2 76.5 ± 9.8 66.8 ± 11.5 <10−6
FVC, pre-bd, % predicted 108.8 ± 13.6 111.1 ± 10.8 100.0 ± 12.0 88.2 ± 9.8 88.7 ± 12.0 <10−6
FEV1/FVC, pre-bd 0.84 ± 0.06 0.80 ± 0.08 0.65 ± 0.08 0.72 ± 0.08 0.64 ± 0.11 <10−6
bd reversibility, % change FEV1 4.1 ± 3.6 10.2 ± 6.3 17.6 ± 7.0 14.8 ± 9.6 32.2 ± 21.9 <10−6
ACQ7 na 0.5 ± 0.5 1.1 ± 0.5 1.2 ± 0.5 2.6 ± 0.9 <10−6
AQLQ na 6.0 ± 1.0 6.0 ± 0.6 5.9 ± 0.8 4.1 ± 1.1 <10−6
FENO, ppb [Geo.Mean] na 35.2 + 28.1/-15.6 43.8 + 36.7/-20.0 16.4 + 9.7/-6.1 37.7 + 47.8/-21.1 <10−6
Blood eosinophils, ×1000/ul
[Geo.Mean]
0.112 + 0.106/-0.054 0.150 + 0.168/-0.079 0.299 + 0.234/-0.131 0.131 + 0.100/-0.057 0.237 + 0.286/-0.130 <10−6
PC20, mg/ml [Geo.Mean] na 2.8 + 11.3/-2.2 0.3 + 1.4/-0.3 2.2 + 7.0/-1.7 0.6 + 2.8/-0.5 <10−6
Blood neutrophils, ×1000/ul
[Geo.Mean]
3.47 + 1.50/-1.05 3.26 + 1.03/-0.78 3.83 + 1.56/-1.11 3.93 + 1.65/-1.16 3.73 + 1.29/-0.96 0.0999
Blood WBC, ×1000/ul
[Geo.Mean]
6.01 + 1.72/-1.34 6.01 + 1.43/-1.16 6.42 + 2.04/-1.55 6.32 + 2.12/-1.59 6.49 + 1.38/-1.14 0.6676
Sputum neutrophils, % of WBCb 53.6 ± 20.1 41.4 ± 33.0 42.2 ± 25.8 63.1 ± 23.8 55.9 ± 21.7 0.0053
Sputum eosinophils, % of WBC
[Geo.Mean]b
0.4 + 0.8/-0.3 1.0 + 4.7/-0.8 7.1 + 18.7/-5.1 0.9 + 3.5/-0.7 3.5 + 10.5/-2.6 <10−6
Serum IgE, RFU [Geo.Mean] 1.0 + 2.1/-0.7 7.6 + 29.5/-6.0 12.6 + 27.5/-8.6 7.1 + 20.3/-5.3 14.4 + 33.2/-10.0 0.0388
Age, years 31.5 ± 9.1 32.5 ± 14.3 42.4 ± 12.0 43.0 ± 11.8 46.8 ± 13.3 0.0002
Age of onset, years na 15.4 ± 13.9 21.0 ± 14.0 22.7 ± 15.2 23.7 ± 18.6 0.1537
Body Mass Index (kg/m2) 24.7 ± 3.3 25.2 ± 3.2 25.7 ± 3.6 26.9 ± 3.7 26.6 ± 4.1 0.1622
Percent of clinical cluster
Mild, no ICS (%) na 93% 16% 27% 11%
Moderate, low-medium ICS (%) na 7% 52% 43% 26% <10−6
Severe, high ICS (%) na 0% 32% 31% 63%
Male (%) 65% 46% 48% 43% 43% 0.9500
Atopic, Phadiatop positive (%) 0% 79% 91% 69% 71% 0.0670
Serum IgE-high, >95th %ile of
controls (%)
0% 71% 86% 69% 83% 0.1692
Sputum Pauci (Eos < %3,
PMN < 60%) (%)b
45% 48% 16% 36% 21%
Sputum Neutr. (Eos < 3,
PMN > =60%) (%)b
50% 30% 13% 43% 17% 0.0012
Sputum Mix (Eos≥ 3%,
PMN > =60%) (%)b
0% 0% 13% 14% 29%
Sputum Eos. (Eos ≥ 3%,
PMN < 60%) (%)b
5% 22% 59% 7% 33%
FENO ≥ 35 ppb (%) na 50% 61% 4% 44% <10−6
Blood eosinophils ≥ 300/ul (%) 6% 21% 50% 6% 34% 2.9 x10−5
FENO ≥ 35 ppb OR Blood eos.
≥ 300/ul (%)
na 57% 84% 10% 57% <10−6
Biopsy CCL26-high (%)c 0% 56% 42% 16% 31% 0.0515
aSummary statistics (mean, or geometric mean where indicated, and standard deviation; or percent of clinical cluster) and p-values from F-test (for mean/geomtric
mean statistics) or x-square statistics for associations among the clinical clusters (not included healthy control cohort) are presented. The 9 clinical and clinical
biomarker variables used in the clustering are presented first, followed by additional clinical, biomarker and demographic variable groupings
bFor sputum differentials, n = 20, 23, 32, 38, and 24 for Healthy cohort and Clusters 1, 2, 3, and 4, respectively
cFor endobronchial biopsy gene expression variables (from Affymetrix HG-U133 + PM array signal intensities), n = 25, 27, 28, 33, and 18 for Healthy cohort and
Clusters 1, 2, 3, and 4, respectively
Significant p values are captured in bold
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deviations of 71.9 ± 10.7 vs. 68.1 ± 9.8, p = 0.011), FVC
(91.6 ± 11.6 vs. 86.5 ± 14.1, p = 0.007), and AQLQ (5.4 ±
1.2 vs. 5.0 ± 1.2, p = 0.018) and higher ACQ-7 (1.6 ± 0.9
vs. 2.3 ± 1.2, p = 0.000045). This also resulted in an
optimum of 4 phenotypes, based on Fc(U)/Dc(U) parti-
tion metrics of 0.776/0.060, 0.810/0.054, 0.837/0.049
(optimal), and 0.800/0.080, for options with 2, 3, 4, and
5 clusters, respectively. The U-BIOPRED phenotypes,
US (U-BIOPRED subset)-1 to US4, shared similar char-
acteristics as A1, A2, A3 and A4, respectively. More
than 75% of participants in each cluster had >81%
probability for their assigned phenotype, and only 2
participants (in Phenotype US1 and US2) had <50%
probability of belonging to their phenotype (Fig. 2). All
clustering variables were significantly associated across
the 4 phenotypes. Figure 6 and Table 3 show clustering,
clinical, biomarker, and demographic variables for the
US1 to US4 clusters.
Phenotype US1 (‘mild, good lung function, early
onset, low inflammation’) was the least symptomatic,
with modest reversible obstruction and good asthma con-
trol. Eosinophilic inflammation was minimal (see Table 3:
FENO, blood eosinophils). US1 was most similar to A1,
albeit with a greater BDR and lower FENO levels, the lat-
ter perhaps due to ICS treatment in US1 but not A1 par-
ticipants. US1 was generally more severe than A1.
Phenotype US2 (‘moderate, hyper-responsive,
eosinophilic’) in general is characterized by reversible
obstruction, uncontrolled asthma, normal FVC, and
predominantly eosinophilic inflammation, with 88% of
participants being FENO-high (≥35 ppb) or blood
eosinophil-high (≥300/μL). For those with induced
sputum, most (69%) had high sputum eosinophils (≥3%
of leukocytes) and few (12%) had high sputum neutro-
phils (≥60% of leukocytes). Phenotype US2 was largely
homologous to phenotype A2.
Phenotype US3 (‘mixed severity, mild reversible
obstruction, non-eosinophilic, neutrophilic’) in gen-
eral had moderately reduced FEV1, reduced mean FVC
(72.9 ± 11.5%% predicted), poor asthma control, and
low-to-modest BDR. Phenotype US3 was neutrophilic
and non-eosinophilic, with only 41% of participants be-
ing FENO-high or blood eosinophil-high, compared to
21% observed in the healthy control group. The majority
of participants (63%) were sputum neutrophil-high, and
few (12.5%) were sputum eosinophil-high. Phenotype US3
was, therefore, largely homologous to Phenotype A3.
Phenotype US4 (‘severe uncontrolled, severe revers-
ible obstruction, mixed granulocytic’) in general was
characterized by marked airflow obstruction, high BDR
with reduced FVC, and very poor asthma control. These
participants were eosinophilic, with 88% of the pheno-
type being FENO-high or blood eosinophil-high and
75% having elevated sputum eosinophils, but 50% also
having high sputum neutrophils. Phenotype US4 was
homologous to Phenotype A4.
Plethysmography data were available in the U-
BIOPRED study (Additional file 1: Table S5). Partici-
pants in Phenotype US4 had relatively normal total
lung capacity but elevated residual volumes (67% higher
than HV), and 24 – 40% higher than Phenotypes US1,
US2, and US3. These results indirectly suggest that the
reduced FVC (mean 81% predicted) was a consequence
of air trapping for Phenotype US4.
Fig. 4 Mean values of clustering and sputum granulocyte variables among clinical clusters. Relative mean values of the indicated variables are
schematically represented for each clinical cluster from ‘best’ (blue) to ‘worst’ (red) values among clusters within the indicated study (coloring for
high-to-low values of variable indicated in right-most column)
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The U-BIOPRED study included several patient-
reported outcome (PRO) questionnaires not included in
the ADEPT study: Epworth sleepiness scale, Hospital Anx-
iety and Depression Scale (HADS), Medication Adherence
Report Scale (MARS), Sino-Nasal Outcome Test (SNOT),
(Additional file 1: Table S5). Phenotypes US1, US3, and
US4 subjects had higher scores for Epworth sleepiness
scale compared to healthy participants (p < 0.05). Except
for phenotype US1, HADS scores were elevated in each
cluster compared to healthy participants (p < 0.05). All 4
clusters had significantly higher SNOT scores (p < 7x10−5),
particularly for clusters US3 and US4. Importantly, all 4
U-BIOPRED phenotypes had similar scores on the MARS
questionnaire, suggesting that clinical and biomarker
differences between the clusters is not largely driven
by differential adherence to medication usage.
Table 2 Clinical, biomarker, and demographic associations among the ADEPT moderate-severe asthma subjects in baseline clinical
cluster groups
Variablea Phenotype A2 (n = 37) Phenotype A3 (n = 36) Phenotype A4 (n = 31) P-value
Mean [Geo.Mean] ± SD
FEV1, pre-bd, % predicted 74.6 ± 8.2 73.8 ± 9.8 65.5 ± 11.5 3.0 x10−4
FVC, pre-bd, % predicted 97.4 ± 9.8 87.4 ± 10.2 88.6 ± 12.2 2.0 x10−4
FEV1/FVC, pre-bd 0.64 ± 0.08 0.70 ± 0.07 0.62 ± 0.10 9.0 x10−4
bd reversibility, % change FEV1 17.3 ± 6.6 16.5 ± 10.5 32.0 ± 21.5 1.1 x10−5
ACQ-7 1.1 ± 0.4 1.3 ± 0.6 2.6 ± 0.9 <10−6
AQLQ 6.0 ± 0.6 5.8 ± 0.9 4.1 ± 1.2 <10−6
FENO, ppb [Geo.Mean] 42.0 + 35.9/-20.9 15.6 + 8.8/-7.9 37.1 + 47.9/-17.8 <10−6
Blood eosinophils, ×1000/ul [Geo.Mean] 0.317 + 0.244/-0.134 0.124 + 0.094/-0.037 0.235 + 0.285/-0.151 <10−6
PC20, mg/ml [Geo.Mean] 0.5 + 1.8/-0.5 2.2 + 8.8/-2.2 0.4 + 1.4/-0.4 1.0 x10−4
Blood neutrophils, ×1000/ul [Geo.Mean] 3.80 + 1.64/-3.80 3.95 + 1.78/-3.95 3.67 + 1.33/-3.67 0.6916
Blood WBC, ×1000/ul [Geo.Mean] 6.34 + 2.10/-0.35 6.35 + 2.28/-0.29 6.44 + 1.39/-0.44 0.9687
Sputum neutrophils, % of WBCb 43.1 ± 26.6 61.6 ± 25.1 56.2 ± 22.1 0.0239
Sputum eosinophils, % of WBC [Geo.Mean]b 7.8 + 20.7/-0.6 0.7 + 2.7/0.0 3.1 + 8.5/-0.2 <10−6
Age, years 43.0 ± 12.3 45.6 ± 10.7 47.9 ± 12.3 0.2340
Age of onset, years 20.9 ± 14.2 23.4 ± 15.5 26.1 ± 18.3 0.4040
Body Mass Index (kg/m2) 25.7 ± 3.6 27.3 ± 3.7 26.8 ± 4.2 0.2308
Percent of clinical cluster group
Mild, no ICS (%) na na na
Moderate, low-medium ICS (%) 62% 58% 29% 0.0135
Severe, high ICS (%) 38% 42% 71%
Male (%) 49% 44% 48% 0.9240
Atopic, Phadiatop positive (%) 92% 72% 71% 0.0530
Sputum Pauci (Eos < %3, PMN < 60%) (%)b 10% 38% 22%
Sputum Neutr. (Eos < 3, PMN > =60%) (%)b 14% 46% 17% 0.0003
Sputum Mix (Eos > =3%, PMN > =60%) (%)b 14% 8% 30%
Sputum Eos. (Eos > =3%, PMN < 60%) (%)b 62% 8% 30%
FENO ≥ 35 ppb (%) 59% 3% 43% 1.8 x10−6
Blood eosinophils ≥ 300/ul (%) 54% 6% 32% 4.1 x10−5
FENO ≥ 35 ppb OR Blood eos. ≥ 300/ul (%) 81% 8% 55% <10−6
Biopsy CCL26-high (%)c 33% 11% 29% 0.2179
aSummary statistics (mean, or geometric mean where indicated, and standard deviation; or percent of clinical cluster group) and p-values from F-test (for mean/
geometric mean statistics) or chisquare statistics for associations among the ADEPT clinical cluster groups, restricted to moderate-severe asthma subjects and
excluding Group 1, are presented. The 9 clinical and clinical biomarker variables used in the clustering are presented first, followed by additional clinical, biomarker
and demographic variable groupings
bFor sputum differentials, n = 29, 24, and 23 for Groups 2, 3, and 4, respectively
cFor endobronchial biopsy gene expression variables (from Affymetrix HG-U133 + PM array signal intensities), n = 21, 20, and 14 for Groups 2, 3, and 4, respectively
Significant p values are captured in bold
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Classification of U-BIOPRED participants to the ADEPT
baseline phenotypes
As an alternate strategy to assess how well the ADEPT
clinical cluster structure fits to an independent study
population, GLMnet-classification model of ADEPT-
asthma baseline clinical clusters (8 clustering variables,
excluding PC20; Model A) was applied to classify the
subset of 397 participants from the U-BIOPRED asthma
subjects (not restricted to ADEPT inclusion criteria and
for whom all clustering clinical data were available). The
classification probabilities for the classified ADEPT clus-
ters are reported in Fig. 2 for both ADEPT (panel c, using
baseline data to demonstrate model performance) and U-
BIOPRED (panel D), with stratification by systemic steroid
use for U-BIOPRED. For ADEPT-asthma, the classifica-
tion concordance to actual clusters was excellent at 96%
overall for all clusters. When applying the classification
model to U-BIOPRED, the probability distributions were
similar to that in ADEPT. Remarkably, the maintenance
OCS group, not represented in ADEPT, also fitted well
into ADEPT phenotype classification structure, with most
participants having >80% probability for their classified
cluster. Importantly, the relative distributions of the 8
clustering variables were similar across the 4 classified
ADEPT clinical phenotypes for U-BIOPRED participants
(Fig. 7) compared to ADEPTasthmatic participants (Fig. 3)
even for participants taking or not taking chronic OCS.
Airway T2 characteristics of asthma phenotypes
In addition to the clinical and clinical biomarker ‘clus-
tering’ variables assessed, plus sputum differential cell
counts, biopsy gene expression was available in 81 of
156 subjects included in the ADEPT clustering. An ac-
tive airway T2 phenotype was defined as the observed
interleukin (IL)-13 activity in endobronchial samples,
indicated by the gene expression of IL-13-inducible
genes. For the ADEPT study, this was specifically evalu-
ated by gene expression of CCL26 in endobronchial bi-
opsies. Despite having the 2nd lowest levels of FENO,
blood eosinophils, and sputum eosinophils, Phenotype
A1 had the highest proportion of participants (56%)
who had high CCL26 gene expression in their endo-
bronchial biopsies (CCL26-high asthmatics defined as
beyond the 95th percentile of healthy control distribu-
tion; Additional file 1: Section S5), followed by Pheno-
type A2, which had slightly fewer (41%) CCL26-high
participants (Table 1). Consistent with being the least
eosinophilic, Phenotype A3 had the least (16%) CCL26-
high participants (Table 1). Phenotype A4 was inter-
mediate, with 32% CCL26-high participants. A similar
pattern among the phenotypes was observed for
POSTN gene expression as an additional indicator of
T2 phenotype (data not shown).
Too few of the 82 U-BIOPRED asthma participants in-
cluded in the clustering had endobronchial biopsy or
brushings samples available for analysis (n = 16 and 17,
respectively). For the 77 of 397 U-BIOPRED participants
classified to ADEPT clusters who had available data on
microarray gene expression in epithelial brushings, the
T2 distributions (defined by IL-13 in vitro stimulation
signature enrichment) were similar to those observed for
ADEPT participants despite the differences in tissue and
indicators for defining T2 status (Data not shown and
Additional file 1: Figure S4), with Phenotypes US2 and
US4 having the highest proportions of T2-high partici-
pants (38%) and Phenotype US3 having the fewest (6%).
Only the U-BIOPRED Phenotype US1 had lower propor-
tions of T2-high participants (21%) compared to Pheno-
type A1 (56%), perhaps a consequence of ICS use in the
U-BIOPRED but not ADEPT asthmatics in Phenotype A1.
Fig. 5 Longitudinal evaluation of ADEPT-asthma clinical phenotype classification. GLMnet-classification model of ADEPT-asthma baseline clinical
phenotypes (7 clustering variables, excluding PC20 and blood eosinophils; Model B) was applied to classify the ADEPT-asthma participants based
on data from the baseline and 3, 6, and 12 month follow-up visits. Each panel presents ADEPT asthma participants assigned to the indicated
clinical phenotypes from the baseline clustering analysis, reporting the phenotype to which they are classified at the indicated follow-up visits
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Discussion
To our knowledge, this is the first study to identify repro-
ducible phenotypes of asthma using data from two entirely
independent cohorts of asthmatic patients. The four
observed phenotypes have clinical relevance, representing
patient subtypes that are commonly encountered in clin-
ical practice, namely mild, well-controlled asthmatics,
moderately-controlled asthmatics with severe AHR, asth-
matic with less reversible airways disease, and severe asth-
matics. The large size of the study, enrolling participants
from across the EU, US and Canada, and the use of
clinical variables that can be obtained easily in any pul-
monary center provides a valuable novel methodological
tool for asthma research.
Initial clustering of the ADEPT study dataset resulted
in four phenotypes that were robust to perturbation and
generally stable over one year. These phenotypes were
further validated in a subset of the U-BIOPRED cohort
dataset, where four remarkably analogous phenotypes
were observed. Importantly, differential biology across
phenotypes was observed which will help develop tai-
lored therapeutic options. Of relevance to current novel
Fig. 6 Clustering variables, sputum granulocytes, and plethysmography in U-BIOPRED clinical phenotypes. The values (y-axis) for the indicated variables
(indicated at top of the plot) are shown for U-BIOPRED asthma participants stratified by fuzzy-PAM clinical phenotypes (x-axis). Data presented as symbols
representing individual participants and summarized by box (inter-quartile range and median) & whiskers (range), with ‘+’ indicating mean. Pre-bd,
pre-bronchodilator; WBC, white blood cells
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Table 3 Clinical, biomarker, and demographic associations among the U-BIOPRED adult asthma clinical clusters
Variablea Healthy
(n = 101)
Cluster US1
(n = 25)
Cluster US2
(n = 32)
Cluster US3
(n = 17)
Cluster US4
(n = 8)
P-value
Mean [Geo.Mean] ± SD
FEV1, % predicted (pre-bd) 101.8 ± 12.9 73.7 ± 7.3 66.6 ± 9.0 67.6 ± 9.9 57.0 ± 8.5 8.8
x10−5
FVC, % predicted (pre-bd) 107.8 ± 13.4 90.9 ± 12.4 91.5 ± 12.6 72.9 ± 11.5 81.2 ± 10.5 6.1
x10−6
FEV1/FVC (pre-bd) 0.79 ± 0.06 0.68 ± 0.08 0.62 ± 0.09 0.79 ± 0.09 0.60 ± 0.06 <10−6
bd reversibility, % change
FEV1
na 13.7 ± 16.7 17.9 ± 9.3 12.9 ± 12.5 45.6 ± 24.5 3.1
x10−6
FENO, ppb [Geo.Mean] 19.9 + 14.2/-8.3 20.8 + 16.0/-9.1 47.4 + 49.8/-24.3 18.1 + 15.0/-8.2 38.8 + 33.4/-17.9 1.6
x10−6
ACQ7 0.0 ± 0.1 1.4 ± 0.7 2.0 ± 0.7 3.3 ± 1.2 4.1 ± 0.8 <10−6
AQLQ 7.0 ± 0.1 6.0 ± 0.6 5.1 ± 0.9 4.0 ± 1.1 3.4 ± 0.8 <10−6
Blood eosinophils, x1000/ul
[Geo.Mean]
0.098 + 0.180/-0.063 0.143 + 0.155/-0.075 0.484 + 0.356/-0.205 0.161 + 0.204/-0.090 0.345 + 0.254/-0.146 <10−6
Blood neutrophils, ×1000/ul
[Geo.Mean]
3.23 + 1.67/-1.10 3.77 + 1.58/-1.11 4.09 + 1.33/-1.00 4.57 + 2.13/-1.45 1.84 ± 0.49 0.2128
Blood WBC, ×1000/ul
[Geo.Mean]
5.64 + 2.04/-1.50 6.41 + 1.62/-1.29 7.39 + 1.79/-1.44 7.83 + 2.24/-1.74 2.71 ± 0.36 0.0236
Sputum neutrophils, % of
WBCb
30.8 + 40.3/-17.4 42.8 ± 28.3 42.0 ± 23.5 73.9 ± 24.2 70.0 ± 21.3 0.0129
Sputum eosinophils, % of
WBC [Geo.Mean]b
0.2 + 0.3/-0.1 0.5 + 4.7/-0.5 6.1 + 44.5/-5.4 0.7 + 4.8/-0.6 6.3 + 21.0/-4.9 0.0123
IgE Total (IU/ml) [Geo.Mean] 25 + 87/-19 121.1 + 377.2/-91.7 245.0 + 1,005.0/-197.0 84.5 + 267.5/-64.2 179.6 + 295.1/-111.7 0.0940
Age 39 ± 13 46 ± 15 49 ± 16 50 ± 12 44 ± 15 0.7000
Age of onset, years na 21 ± 18 26 ± 19 29 ± 19 14 ± 12 0.2028
Body Mass Index (kg/m2) 25.3 ± 3.6 27.6 ± 5.4 27.6 ± 5.8 30.9 ± 7.8 27.1 ± 4.8 0.2408
Percent of clinical cluster group
Severe / Non-severe asthma
(N / N)
na 11 / 14 25 / 7 16 / 1 8 / 0 0.0004
Male (%) 61% 36% 34% 29% 25% 0.9276
Atopic, Skin prick test or serum
IgE-RAST (%)
45% 100% 86% 88% 100% 0.5816
Sputum Pauci (Eos < %3,
PMN < 60%) (%)b
76% 42% 25% 25% 0% 0.0496
Sputum Neutr. (Eos < 3,
PMN > =60%) (%)b
24% 33% 6% 63% 25%
Sputum Mix (Eos > =3%,
PMN > =60%) (%)b
0% 0% 6% 0% 25%
Sputum Eos. (Eos > =3%,
PMN < 60%) (%)b
0% 25% 63% 13% 50%
FENO ≥ 35 ppb (%) 18% 24% 59% 12% 50% 0.0032
Blood eosinophils ≥ 300/ul (%) 7% 20% 75% 35% 63% 0.0003
FENO ≥ 35 ppb OR Blood eos.
≥ 300/ul (%)
21% 32% 88% 41% 88% 3.3
x10−5
aSummary statistics (mean, or geometric mean where indicated, and standard deviation; or percent of clinical cluster group) and p-values from F-test (for mean/
geometric mean statistics) or chi-square statistics for associations among the U-BIOPRED adult asthma clinical cluster groups are presented. The 8 clinical and
clinical biomarker variables used in the clustering are presented first, followed by additional clinical, biomarker and demographic variable groupings
bFor sputum differentials, n = 12, 16, 8, and 4 for the healthy control cohort and Groups A, B, and C, and D, respectively
Significant p values are captured in bold
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therapies that target T2 immune mechanisms, the pheno-
types could be differentiated in respect of expression of
gene sets that are characteristic of the pathobiology driven
by the T2 cytokine, IL-13. Phenotype A1, was remarkably
similar to Phenotype US1 from the U-BIOPRED valid-
ation set. The low degree of airway inflammation in A1
was commensurate with absence of a decision to start
controller medications, while in the US1 phenotype,
where all the asthmatics were on ICS, this suggested
adequate suppression of airway inflammation and, conse-
quently, good disease control. Of note, the A1 phenotype
had the highest proportion of T2 high asthmatics even
though their levels of exhaled NO, proposed as good
biomarkers of T2 inflammation [20], were relatively low.
This suggests that T2 inflammation, on its own, may not
be a determinant of clinical severity. Given the good
Fig. 7 Clustering variables in U-BIOPRED participants classified to ADEPT clinical phenotypes. The values (y-axis) for the indicated variables (indicated at top
of plot) are shown U-BIOPRED healthy controls and asthma participants classified to ADEPT clinical phenotypes (Model A) (x-axis), stratified chronic systemic
corticosteroid (SCS) use (blue, no; red, yes). Data presented as symbols representing individual participants and summarized by box (inter-quartile range
and median) & whiskers (range), with ‘+’ indicating mean. Pre-bd, pre-bronchodilator; WBC, white blood cells
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clinical characteristics of this phenotype, there seems to
be minimal need for new therapies, although this pheno-
type could be targeted for disease interception.
The asthmatics in Phenotype A2, based on their ACQ-
7 scores (mean 1.1), were between the cut-off for good
(<0.75) and poor control (>1.5), suggesting less than op-
timal control. With respect to underlying pathobiology,
their gene expression profile was highly skewed towards
T2 inflammation. Consistent with previous reports in
mild, steroid-naive asthmatics [21], the high expression
of IL-13 induced genes was associated with the highest
eosinophilic profile amongst all four phenotypes. The
preserved lung function and asthma control, but severe
AHR may represent “brittle” asthma, a recognized pa-
tient phenotype. Given that these asthmatics were on
regular treatment with corticosteroids, the high T2 pro-
file suggests a significant degree of steroid insensitivity;
therefore, treatment with biologics or other drugs target-
ing T2 inflammation might be indicated in this pheno-
type to achieve improved control.
Phenotype A3 had reduced lung capacity and lower BDR
(compared to A2 and A4), which could suggest more
extensive tissue remodeling. The asthmatics in this pheno-
type tended to be more neutrophilic and could, therefore, be
viewed as having phenotypic similarities to COPD, with dis-
ease potentially driven more by infection than atopy. Con-
sistent with the neutrophilic, rather than eosinophilic,
nature of the disease, T2 gene expression was the lowest of
all phenotypes. While not studied in ADEPT, the role of the
microbiome in the airway or GI tract might be important,
supporting evaluation of alternative anti-inflammatories e.g.
macrolide antibiotics in this phenotype [22]. This phenotype
has few therapeutic options at present so further study of
the underlying mechanisms and how these impacts on clin-
ical expression are needed.
Of all the observed phenotypes, Phenotype A4 was
the most severe, with ACQ (mean 2.6) well above the
cut-off for poor control and with 63% of participants
classified as severe on enrollment. These asthmatics
had the worse mean FEV1 (66%) and were severely
hyper-responsive. Their sputum had a mixed granulo-
cytic profile, with both neutrophil and eosinophil
counts being high. Of importance, they had an airway
T2-high profile, despite treatment with ICS, which
could, like A2, represent relative steroid insensitivity.
Patients with this profile are the commonest partici-
pants included in recent asthma studies for novel T2-
inflammation focused therapeutics, e.g. anti-IL-13 and
anti- IL-5 monoclonal antibodies [23, 24]. These asth-
matics had the second highest concentrations of
FENO. Thus, those asthmatics in this phenotype with
high levels of predictive biomarkers such as eosino-
philia and FENO may well respond to therapies tar-
geting IL-13 biology and/or eosinophilic inflammation
[23, 25]. Alternatively, high FENO concentrations could
represent poor adherence to treatment with ICS [26].
There are many possible influences on stability of phe-
notypes such as allergen exposure, air pollution, as well as
emergent changes in asthma medications, and viral infec-
tions. Thus, it is interesting that ADEPT participants
remained relatively stable for their phenotype assignments
throughout the 12-month duration of the study, suggest-
ing that the phenotypes represent different disease driving
biological mechanism but their specific combinations
within a phenotype remain stable over time. Phenotype
A4 was the least stable of the groups, and we would
speculate that periods of reduced environmental triggers
could improve control in this most severe group, resulting
in a shift to Phenotype A2. Alternatively, improved re-
sponsiveness to inhaled steroids with resulting reduction
in T2 inflammation (whether environmentally based or
from improved adherence during the study) could result
in a shift to Phenotype A3. However, the appropriate data
to support such possibilities are not available and thus
such explanations remain speculative.
This study makes valuable observations when comparing
two entirely independent cohorts where participants are
not matched a priori. Participants in the ADEPT study were
selected on the basis of steroid therapy and significant ob-
struction (FEV1 ≤ 80% of predicted), in order to match
standard interventional clinical trial enrollment criteria. At
the same time, more restrictive limits were placed on other
clinical parameters such as BMI (≤32 kg/m2) and smoking
asthmatics were excluded. U-BIOPRED had a much
broader representation of the overall asthmatic population,
including severe asthmatics on maintenance OCS treat-
ment and much lower FEV1. Because of these differences,
the U-BIOPRED primary validation set only included those
participants most similar to those in ADEPT. Although
PC20 data were not available for most of the U-BIOPRED
participants, the four ADEPT phenotypes largely mapped
to the resultant 4 U-BIOPRED phenotypes for clinical vari-
ables. However, when applying the ADEPT classification
model to a larger subset of the adult participants in U-
BIOPRED cohort, the asthmatics on maintenance OCS and
smoking-associated severe asthma also fitted well into the
ADEPT phenotype classification structure, with similar
relative distributions of the 8 clustering variables across the
4 classified ADEPTclinical phenotypes.
When considering the underlying biology, there was
substantial homology between Phenotypes A1, A2, A3,
and A4 and Phenotypes US1, US2, US3 and US4, re-
spectively, with similar homology for most inflammatory
variables. In comparison to Phenotype A2, the equiva-
lent US2 phenotype from U-BIOPRED, had very similar
bronchodilator responsiveness, albeit slightly worse pre-
bronchodilator FEV1 (mean 66%). The T2 profile in
Phenotype US2 was similarly skewed towards T2. Both
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Phenotypes A3 and US3 shared features with COPD
(lower BDR compared to A2 and A4, low FENO, and neu-
trophilia). However, despite relatively low eosinophilic
inflammation in both A1 and US1, FENO and airway T2-
high status tended to be higher in A1 but low in US1,
likely a consequence of ICS requirement in U-BIOPRED
but not in ADEPT. This observation suggests that FENO
levels may be more directly associated with lower airway
T2 activity than eosinophilic inflammation per se. We
have observed that the T2-high phenotype is a subset of a
broader eosinophilic phenotype group in ADEPT and U-
BIOPRED studies [27], consistent with results from Choy
et al. [28] in mild asthma (evaluating T2 phenotype status
by POSTN, SERPINB2, and CLCA1 expression in endo-
bronchial brushings).
T2 inflammation is a major characteristic defining the
clusters, but mainly distinguishes Phenotype A3 (low T2
inflammation) from the other 3 phenotype groups. Pheno-
types A1, A2, and A4 are then clinically distinguished by
degree of asthma control and airflow limitations. Ideally
T2 and eosinophilic inflammation would be established
from airway mucosal and sputum sampling, but these are
difficult to evaluate in a standard clinical setting. Blood
eosinophils, FENO, and potentially serum proteins could
serve as surrogates to establish these phenotypes, but
alone are insufficient to define such. Combinations of the
surrogates, as utilized in the classification of the pheno-
type groups, are needed for more accurate estimation of
T2 and eosinophilic phenotypes.
The variables selected for clustering in this study were
different from those in previous reports (Additional file 1:
Table S1), applying variables readily measured in clinical
practice and trials that represent the current clinical pres-
entation of asthma, as opposed to demographic and
historical aspects of the disease. Likewise, although gender
and smoking history may be associated with disease, they
do not directly represent the pathology of asthma. Post-
hoc perturbation analyses (not reported) assessing the
impact of adding in additional demographic, historical,
and treatment attributes (e.g., gender, age, atopy, asthma
age-of-onset, BMI, ICS dose; 20 variables total), resulted
in weaker clustering (based on distance metrics and clus-
ter membership probabilities), with qualitatively similar
clinical associations as reported for the ADEPT asthma
phenotypes (65% concordance of the most closely analo-
gous clusters with the reported ADEPT asthma pheno-
types). FENO was an influential variable in the clustering.
Inclusion of FENO could potentially indicate steroid
insensitivity and/or a basal non-inflammatory phenotype.
Given that FENO and blood eosinophil levels were not
higher in cluster A1 (mostly no ICS) compared to clusters
2 and 4 (low-medium and high ICS), FENO and blood eo-
sinophil levels are not simply an indicator of ICS use.
Compliance was not formally monitored in these studies.
However, suppression of B cell and T cell lineage gene ex-
pression in biopsies below levels in healthy controls and
mild asthmatics (not taking ICS), and suppression of mast
cell lineage gene expression below that in mild asthma
(data not shown), suggests that most subjects in the mod-
erate and severe asthma groups were compliant in taking
ICS, at least around the time of biopsy. The fitting of the
U-BIOPRED severe asthmatics on oral CS to the clusters
furthers confidence that the cluster formations were not
overly influenced by lack of compliance to steroids. Never-
theless, even in the best of circumstances, compliance can
only be evaluated over the short-term and imperfectly in
absence of inpatient-monitoring.
The strength of this study is represented by the inde-
pendent, external validation and the longitudinal stability
assessment. Nevertheless, there are also limitations. The
actual prevalence of the clinical clusters cannot be dir-
ectly estimated because participants were not randomly
recruited from the general asthma population. ADEPT
had strict inclusion/exclusion criteria to restrict enroll-
ment to patients likely to be enrolled in interventional
clinical studies. Thus morbidly obese participants, smok-
ing participants and chronic OCS-treated participants
are not represented in ADEPT. In contrast, U-BIOPRED
did include smokers and chronic OCS treated patients,
with almost 50% of asthmatics on chronic OCS therapy.
These features in fact predominated in the distinction of
the 4 clinical clusters that have been reported with the
U-BIOPRED cohort [29] (Additional file 1: Section S12).
Indeed, 4 clusters were identified, of which the first con-
sisted of well-controlled mild-to-moderate asthmatics,
while the 3 other clusters consisting of predominantly
severe asthma patients were characterised by 2 clusters
of chronic airflow obstruction, one with late-onset
asthma in predominant smokers/ex-smokers with high
BMI and the other in non-smokers with high OCS use;
the fourth cluster consisted of predominantly obese fe-
male patients with uncontrolled asthma and increased
exacerbations, but with normal lung function [29].
Conclusion
In summary, we have provided evidence for four pheno-
types that are stable over time and are differentiated by
both clinical severity, response to their prescribed treat-
ment and the underlying T2 gene expression profile.
Critically, these phenotypic groups were validated in an
independent asthma cohort. Further extensive gene ex-
pression data and other ‘omics’ analyses remain available
for more in-depth evaluation of molecular profiles asso-
ciated with these newly defined clinical phenotypic
groups. Focusing on the biology of each phenotype and
understanding the unmet need will aid in developing tai-
lored therapies.
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studies. Table S2. Clinical and demographic characteristics of ADEPT and
U-BIOPRED severity cohorts. Table S3. Linear predictor function coefficients
for classification to ADEPT-asthma baseline clinical clusters. Table S4. IL-13
in vitro stimulation (IVS) signature. Table S5. Plethysmography and PRO
variable associations among the U-BIOPRED adult asthma clinical clusters.
Figure S1. (A). Longitudinal ADEPT cluster classifications discordant with
baseline Cluster A1. Figure S1. (B). Longitudinal ADEPT cluster classifications
discordant with baseline Cluster A2. Figure S1. (C). Longitudinal ADEPT
cluster classifications discordant with baseline Cluster A3. Figure S1. (D).
Longitudinal ADEPT cluster classifications discordant with baseline Cluster
A4. Figure S2. Characterization of selected subjects changing ADEPT cluster
classifications. Figure S3. Characterization of selected subjects with stable
ADEPT cluster classifications. Figure S4. IL-13 activity in U-BIOPRED participants
classified to ADEPT clinical clusters. (XLSX 461 kb)
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